"Sponsored by10:20 Clinically Relevant Immunogenicity Testing of Biologicals ??? Hypersensitivity Risks and IgE MeasurementJ??rgen Dahlstr??m, Ph.D., Scientific Director, Immune Response Diagnostics, Phadia, SwedenThe dramatic increase in the use of recombinant monoclonal antibodies and other biopharmaceuticals in the treatment of cancers and autoimmune diseases such as inflammatory bowel disease a" . . . .